Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

ROIV

Roivant Sciences Ltd

Dec 29 • 11:26AM ET

21.88

-0.35 -1.60 %

Healthcare • Biotechnology • United Kingdom • NASD

Peers: VRTX REGN BIIB BMRN ALNY CRSP INCY NBIX IONS EDIT

| Held by: IJH VTI VB VBK XBI VXF MDY IBB SPMD DFAS

Index	-	P/E	-	EPS (ttm)	-0.55	Insider Own	37.10%	Shs Outstand	689.70M	Perf Week	-2.39%
Market Cap	15.21B	Forward P/E	-	EPS next Y	-1.26	Insider Trans	-7.67%	Shs Float	437.46M	Perf Month	4.82%
Enterprise Value	11.37B	PEG	-	EPS next Q	-0.30	Inst Own	63.51%	Short Float	4.01%	Perf Quarter	44.87%
Income	-373.97M	P/S	748.35	EPS this Y	-365.48%	Inst Trans	0.61%	Short Ratio	2.16	Perf Half Y	94.10%
Sales	20.33M	P/B	3.46	EPS next Y	-13.14%	ROA	-12.44%	Short Interest	17.52M	Perf YTD	84.91%
Book/sh	6.32	P/C	3.47	EPS next 5Y	-25.94%	ROE	-14.73%	52W High	23.47 -6.80%	Perf Year	82.29%
Cash/sh	6.31	P/FCF	-	EPS past 3/5Y	42.73% -99.51%	ROIC	-8.40%	52W Low	8.73 150.57%	Perf 3Y	201.72%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-19.30% -	Gross Margin	70.12%	Volatility	2.37% 3.41%	Perf 5Y	118.75%
Dividend TTM	-	EV/Sales	559.16	EPS Y/Y TTM	-109.22%	Oper. Margin	-5659.41%	ATR (14)	0.70	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	33.70	Sales Y/Y TTM	-83.82%	Profit Margin	-1839.58%	RSI (14)	54.93	Recom	1.36
Dividend Gr. 3/5Y	- -	Current Ratio	33.70	EPS Q/Q	46.74%	SMA20	1.33%	Beta	1.23	Target Price	26.60
Payout	-	Debt/Eq	0.02	Sales Q/Q	-64.89%	SMA50	6.78%	Rel Volume	0.29	Prev Close	22.23
Employees	750	LT Debt/Eq	0.02	Earnings	Nov 10 BMO	SMA200	55.60%	Avg Volume	8.12M	Price	21.88
IPO	Dec 08, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.87% -72.04%	Trades		Volume	783,728	Change	-1.60%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-02-25	Initiated	Citigroup	Buy	$16
Jul-10-25	Resumed	Goldman	Buy	$19
Feb-15-24	Initiated	Wolfe Research	Outperform	$17
Jan-05-24	Initiated	Piper Sandler	Overweight	$20
Dec-12-23	Initiated	Deutsche Bank	Buy	$14
Oct-17-23	Initiated	Guggenheim	Buy	$17
Jun-08-23	Initiated	BofA Securities	Neutral	$10.50
Oct-27-22	Initiated	JP Morgan	Overweight	$7
May-23-22	Initiated	SVB Leerink	Outperform	$6
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight	$15
Dec-15-21	Initiated	Goldman	Buy	$15
Nov-08-21	Initiated	H.C. Wainwright	Buy	$14
Oct-28-21	Initiated	Citigroup	Buy	$11
Oct-26-21	Initiated	Truist	Buy	$15
Oct-26-21	Initiated	Jefferies	Buy	$10
Oct-26-21	Initiated	Cowen	Outperform

Show Previous Ratings

Dec-22-25 08:10AM	Insider Action: Multimillion-dollar sell-offs across major U.S. companies (CNBC TV)
Dec-11-25 07:30AM	Roivant Highlights Continued Pipeline Progress and Outlook for Company's Next Phase of Growth at 2025 Investor Day (GlobeNewswire) +5.43%
Dec-10-25 02:00AM	A Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
02:00AM	A former Roivant spinout bets on AI-designed drugs for immune conditions (BioPharma Dive)
Nov-10-25 02:01PM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
08:25AM	Loading…
08:25AM	Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update (GlobeNewswire)
Nov-06-25 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 09:10AM	LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 07:30AM	Do You Believe in the Growth Prospects of Roivant Sciences Ltd. (ROIV)? (Insider Monkey)
Oct-27-25 04:10PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 (GlobeNewswire)
Oct-21-25 05:52AM	Wall Street Has a Mixed Opinion on Roivant Sciences Ltd (ROIV) (Insider Monkey)
Oct-04-25 04:54PM	Roivant's Brepocitinib Phase 3 Dermatomyositis Trial Hits Primary and All Key Secondary Endpoints (Insider Monkey)
Sep-29-25 08:01PM	Vivek Ramaswamy's Bitcoin Play Just Got Bigger: This $1.3B Deal Could Signal Corporate Crypto's Next Phase (Benzinga)
Sep-23-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Roivant Sciences Ltd. (ROIV) is a Great Choice (Zacks)
10:21AM	Loading…
Sep-22-25 10:21AM	Ramaswamy-backed Strive to buy Semler in $1.3 billion deal all stock deal, boosting Bitcoin holdings (Reuters)
Sep-18-25 10:47AM	Roivant Sciences (ROIV) Hits New All-Time High as Drug Candidate Clinical Trial Posts Impressive Results (Insider Monkey)
10:34AM	Montes Archimedes Acquisition (ROIV) Surges 7.8%: Is This an Indication of Further Gains? (Zacks)
Sep-17-25 04:11PM	Roivant Flirts With A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease (Investor's Business Daily) +7.76%
12:49PM	Why Roivant Sciences Stock Is Soaring Today (Motley Fool)
07:00AM	Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM) (GlobeNewswire)
Sep-14-25 04:00AM	Vivek Ramaswamy Sells $22.7 Million of Roivant Sciences Stock (Barrons.com)
Sep-11-25 04:30PM	Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List (GlobeNewswire)
11:11AM	Roivant Sciences Ltd. (ROIV) Wins Orphan Drug Status in Japan for Mosliciguat (Insider Monkey)
Sep-03-25 01:01PM	Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients (GlobeNewswire)
Aug-28-25 11:49PM	Roivant Sciences (ROIV) Announces Q1 2025 Business Update (Insider Monkey)
Aug-12-25 06:42PM	Why Roivant Sciences Stock Bounced Back on Tuesday (Motley Fool)
03:02AM	Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Aug-11-25 04:58PM	Why Roivant Sciences Stock Was Slipping on Monday (Motley Fool)
08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Loading…
07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update (GlobeNewswire)
Aug-08-25 09:17AM	What To Expect From Roivant Sciences Ltd (ROIV) Q1 2026 Earnings (GuruFocus.com)
Aug-07-25 06:15PM	Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Aug-05-25 08:10AM	Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-28-25 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 (GlobeNewswire)
Jul-24-25 11:47PM	Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with 'Buy' Rating (Insider Monkey)
Jul-11-25 06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
Jun-24-25 12:45PM	Roivant Sciences Subsidiary Pulmovant Publishes Positive Phase 1 Data for Inhaled PH Treatment Mosliciguat (Insider Monkey)
Jun-16-25 07:00AM	Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics (GlobeNewswire)
Jun-09-25 04:05PM	Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis (GlobeNewswire)
May-29-25 08:15AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +6.40%
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update (GlobeNewswire)
May-28-25 02:17PM	H.C. Wainwright Keeps Buy Rating on Roivant Sciences (ROIV) Stock (Insider Monkey)
09:15AM	What To Expect From Roivant Sciences Ltd (ROIV) Q4 2025 Earnings (GuruFocus.com)
May-15-25 05:15PM	Gossamer Bio (GOSS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025 (GlobeNewswire)
May-14-25 05:40PM	Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-08-25 07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-06-25 06:20AM	Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar? (Zacks)
May-02-25 10:37AM	Roivant Sciences Ltd. (ROIV): Among David Einhorn's Stock Picks with Huge Upside Potential (Insider Monkey)
Apr-29-25 11:35AM	Roivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
Apr-23-25 12:13PM	Roivant Sciences: Primed For Growth With A De-Risked Pipeline (Seeking Alpha)
Apr-21-25 04:08PM	Immunovant Dives On Its C-Suite Sweep, Narrowed Plans For Leading Drug (Investor's Business Daily)
10:18AM	Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift (Investor's Business Daily)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjogren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
07:00AM	Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sj gren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402 (GlobeNewswire)
Apr-14-25 06:20AM	Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now? (Zacks)
Apr-11-25 03:07PM	Is Roivant Sciences Ltd. (ROIV) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? (Insider Monkey)
10:04AM	Certara (CERT) Soars 8.0%: Is Further Upside Left in the Stock? (Zacks)
Apr-10-25 05:08PM	Roivant Sciences Ltd. (ROIV): Among the Best Low Priced Growth Stocks to Invest In (Insider Monkey)
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
Mar-29-25 04:00PM	Is Roivant Sciences (ROIV) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-25-25 02:12PM	Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn? (InsiderMonkey)
Mar-19-25 04:04PM	Roivant And Immunovant Won't Seek Approval Despite Phase 3 Win. Why Shares Rose. (Investor's Business Daily)
09:26AM	Roivant, Immunovant Succeed In Phase 3. But There's A Twist And Shares Tumbled. (Investor's Business Daily)
07:45AM	Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies (GlobeNewswire)
Mar-18-25 04:32PM	Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs (GlobeNewswire)
Mar-03-25 09:15AM	Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna (GlobeNewswire) -5.31%
Feb-25-25 08:00AM	Early Warning Report Issued Pursuant to National Instrument 62 103: Roivant announces Resignation and Replacement of Arbutus Board (GlobeNewswire)
Feb-12-25 10:00AM	Roivant Sciences price target lowered to $12 from $13 at BofA (TipRanks)
Feb-10-25 07:00AM	Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update (GlobeNewswire)
Feb-07-25 07:06AM	What To Expect From Roivant Sciences Ltd (ROIV) Q3 2025 Earnings (GuruFocus.com)
Feb-03-25 07:00AM	Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care (GlobeNewswire)
Jan-29-25 04:05PM	Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025 (GlobeNewswire)
Jan-15-25 08:49PM	Vivek Ramaswamy Open to Replacing JD Vance in Senateif Offered (The Wall Street Journal)
Jan-12-25 09:40AM	Is Roivant Sciences (ROIV) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-02-25 03:28AM	Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing (Insider Monkey)
Dec-03-24 07:00AM	Roivant Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
07:00AM	Kinevant Sciences Announces Topline Results from Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis (GlobeNewswire)
Nov-15-24 05:01PM	Vivek Ramaswamy's Net Worth Is 9 Figures See How the DOGE Co-Lead Made His Millions (Investopedia)
Nov-12-24 07:00AM	Roivant Reports Financial Results for the Second Quarter Ended September 30, 2024, and Provides Business Update (GlobeNewswire)
Nov-11-24 07:04AM	Roivant Sciences Ltd (ROIV) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-29-24 04:35PM	Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Oct-28-24 09:25AM	Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-18-24 07:30AM	Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA (tapinarof) Cream, 1% (GlobeNewswire)
Sep-10-24 06:30AM	Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator (GlobeNewswire)
06:30AM	Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress (GlobeNewswire)
Sep-09-24 07:00AM	Roivant Provides Update on Graves' Disease Development Program (GlobeNewswire)
Sep-04-24 06:55PM	The Federal Reserve should refresh its mandate: Former presidential candidate Vivek Ramaswamy (Yahoo Finance)
Aug-08-24 07:00AM	Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update (GlobeNewswire) +6.69%
Jul-25-24 04:05PM	Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024 (GlobeNewswire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:53AM	ROIV Stock Earnings: Roivant Sciences Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:20AM	Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update (GlobeNewswire)
May-27-24 06:28PM	Institutional Investors are Betting on Roivant Sciences (NASDAQ:ROIV) (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-16-24 04:05PM	Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 (GlobeNewswire)
May-08-24 02:43AM	Greenlight Capital Initiated a Position in Roivant Sciences (ROIV) in Q1 (Insider Monkey)

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ERIC VENKER	Officer	Dec 24 '25	Proposed Sale	22.53	75,000	1,689,562		Dec 29 09:36 AM
FRANK M TORTI	Officer	Dec 24 '25	Proposed Sale	22.47	64,891	1,458,373		Dec 29 09:05 AM
RICHARD PULIK	Officer	Dec 23 '25	Proposed Sale	22.45	260,000	5,835,726		Dec 23 04:19 PM
RICHARD PULIK TRUST	Officer	Dec 23 '25	Proposed Sale	22.39	146,731	3,285,755		Dec 23 04:07 PM
ERIC VENKER	Officer	Dec 23 '25	Proposed Sale	22.45	200,000	4,490,540		Dec 23 04:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Option Exercise	12.68	59,513	754,625	18,896,060	Dec 19 09:04 PM
Sukhatme Mayukh	President & CIO	Dec 17 '25	Sale	23.09	26,831	619,528	18,869,229	Dec 19 09:04 PM
Gold Daniel Allen	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:54 PM
Gold Daniel Allen	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:54 PM
MANCHESTER KEITH S	Director	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:52 PM
MANCHESTER KEITH S	Director	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:52 PM
QVT Financial LP	Director by Deputization	Dec 16 '25	Sale	23.04	917,282	21,129,619	17,130,445	Dec 18 07:41 PM
QVT Financial LP	Director by Deputization	Dec 17 '25	Sale	23.07	777,332	17,935,595	16,353,113	Dec 18 07:41 PM
Gline Matthew	CEO	Dec 15 '25	Option Exercise	12.16	3,870,659	47,062,049	19,559,933	Dec 17 09:00 PM
Gline Matthew	CEO	Dec 15 '25	Sale	21.68	1,740,000	37,723,200	17,290,820	Dec 17 09:00 PM
Sukhatme Mayukh	Officer	Dec 17 '25	Proposed Sale	23.09	26,831	619,488		Dec 17 05:09 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Option Exercise	12.68	4,672,724	59,250,140	38,326,479	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Option Exercise	12.68	1,869,691	23,707,682	35,523,447	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Option Exercise	12.68	832,453	10,555,504	34,486,208	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 12 '25	Sale	21.96	1,975,858	43,389,842	36,350,621	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 11 '25	Sale	21.64	774,142	16,752,433	34,749,305	Dec 15 09:34 PM
Ramaswamy Vivek	10% Owner	Dec 15 '25	Sale	22.05	353,745	7,800,077	34,132,463	Dec 15 09:34 PM
Gline Matthew	Officer	Dec 15 '25	Proposed Sale	21.68	1,740,000	37,723,200		Dec 15 04:36 PM
Roivant Sciences Ltd.	Director	Dec 12 '25	Buy	21.00	16,666,666	349,999,986	113,317,007	Dec 12 05:17 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Option Exercise	3.85	200,000	770,000	1,697,908	Dec 11 09:00 PM
Venker Eric	President & Immunovant CEO	Dec 09 '25	Sale	20.85	200,000	4,170,000	1,497,908	Dec 11 09:00 PM
Venker Eric	Officer	Dec 09 '25	Proposed Sale	20.85	200,000	4,169,131		Dec 09 04:49 PM
MANCHESTER KEITH S	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:24 PM
Gold Daniel Allen	Director	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:22 PM
QVT Financial LP	Director by Deputization	Nov 19 '25	Sale	20.23	1,300,000	26,304,500	18,047,727	Nov 21 08:15 PM
Ramaswamy Vivek	10% Owner	Nov 14 '25	Sale	20.33	1,027,670	20,892,531	34,193,406	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 17 '25	Sale	20.51	539,650	11,068,222	33,653,756	Nov 17 05:52 PM
Ramaswamy Vivek	10% Owner	Nov 13 '25	Sale	20.81	287,283	5,978,359	35,221,076	Nov 17 05:52 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Option Exercise	3.85	200,000	770,000	1,704,959	Nov 07 09:00 PM
Venker Eric	President & Immunovant CEO	Nov 07 '25	Sale	20.22	200,000	4,044,000	1,504,959	Nov 07 09:00 PM
Venker Eric	Officer	Nov 07 '25	Proposed Sale	20.22	200,000	4,043,960		Nov 07 03:15 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Option Exercise	15.85	414,683	6,572,726	1,919,642	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Option Exercise	15.85	318,282	5,044,770	1,823,241	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Option Exercise	15.85	118,418	1,876,925	1,623,377	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 15 '25	Sale	16.93	414,683	7,020,583	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 16 '25	Sale	17.05	318,282	5,426,708	1,504,959	Oct 17 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 17 '25	Sale	17.06	118,418	2,020,211	1,504,959	Oct 17 09:00 PM
Venker Eric	Officer	Oct 17 '25	Proposed Sale	17.06	118,418	2,020,171		Oct 17 04:01 PM
Venker Eric	Officer	Oct 16 '25	Proposed Sale	17.05	318,282	5,425,645		Oct 16 04:37 PM
Venker Eric	Officer	Oct 15 '25	Proposed Sale	16.93	414,683	7,021,429		Oct 15 04:23 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Option Exercise	15.85	104,940	1,663,299	1,609,899	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Option Exercise	15.85	20,727	328,523	1,525,686	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 09 '25	Sale	16.30	104,940	1,710,522	1,504,959	Oct 14 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 13 '25	Sale	16.25	20,727	336,814	1,504,959	Oct 14 09:00 PM
Venker Eric	Officer	Oct 13 '25	Proposed Sale	16.25	20,727	336,877		Oct 14 08:51 AM
Venker Eric	Officer	Oct 09 '25	Proposed Sale	16.30	104,940	1,710,040		Oct 09 04:12 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Option Exercise	7.21	355,161	2,559,093	1,860,120	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Option Exercise	13.29	171,396	2,277,775	1,676,355	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Option Exercise	8.07	138,602	1,119,164	1,643,561	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 07 '25	Sale	16.15	355,161	5,735,850	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 06 '25	Sale	16.34	171,396	2,800,611	1,504,959	Oct 08 09:00 PM
Venker Eric	President & Immunovant CEO	Oct 08 '25	Sale	16.20	138,602	2,245,352	1,504,959	Oct 08 09:00 PM
Venker Eric	Officer	Oct 08 '25	Proposed Sale	16.20	138,602	2,244,797		Oct 08 04:15 PM
Venker Eric	Officer	Oct 07 '25	Proposed Sale	16.15	355,161	5,734,289		Oct 07 04:34 PM
Venker Eric	Officer	Oct 06 '25	Proposed Sale	16.34	171,396	2,800,365		Oct 06 04:46 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Option Exercise	3.85	1,000,000	3,850,000	2,653,585	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Option Exercise	3.85	562,374	2,165,140	2,532,141	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 19 '25	Sale	14.95	683,818	10,223,079	1,969,767	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 23 '25	Sale	14.83	611,000	9,061,130	1,504,959	Sep 23 09:00 PM
Venker Eric	President & Immunovant CEO	Sep 22 '25	Sale	14.99	416,182	6,240,568	2,115,959	Sep 23 09:00 PM
Venker Eric	Officer	Sep 23 '25	Proposed Sale	14.94	611,079	9,129,520		Sep 23 09:45 AM
ERIC VENKER	Officer	Sep 22 '25	Proposed Sale	14.99	316,182	4,741,054		Sep 22 04:20 PM
Venker Eric	Officer	Sep 22 '25	Proposed Sale	15.01	100,000	1,501,339		Sep 22 04:07 PM
ERIC VENKER	Officer	Sep 19 '25	Proposed Sale	14.95	683,818	10,220,412		Sep 19 04:32 PM
Gline Matthew	CEO	Sep 18 '25	Buy	15.07	3,315	49,957	17,287,081	Sep 18 07:28 PM
Ramaswamy Vivek	10% Owner	Sep 03 '25	Sale	12.50	1,195,000	14,937,500	36,089,108	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 05 '25	Sale	12.96	385,816	5,000,175	35,508,359	Sep 05 05:01 PM
Ramaswamy Vivek	10% Owner	Sep 04 '25	Sale	12.92	194,933	2,518,534	35,894,175	Sep 05 05:01 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Option Exercise	3.85	100,000	385,000	1,753,585	Aug 22 09:00 PM
Venker Eric	President & Immunovant CEO	Aug 20 '25	Sale	11.72	100,000	1,172,000	1,653,585	Aug 22 09:00 PM
Venker Eric	Officer	Aug 20 '25	Proposed Sale	11.72	100,000	1,172,120		Aug 20 04:30 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jul 23 09:00 PM
Venker Eric	President & Immunovant CEO	Jul 21 '25	Sale	11.52	100,000	1,152,000	1,462,223	Jul 23 09:00 PM
Venker Eric	Officer	Jul 21 '25	Proposed Sale	11.52	100,000	1,151,942		Jul 21 04:34 PM
Venker Eric	President & COO	Jun 20 '25	Option Exercise	3.85	100,000	385,000	1,562,223	Jun 24 09:01 PM
Venker Eric	President & COO	Jun 20 '25	Sale	11.45	100,000	1,145,000	1,462,223	Jun 24 09:01 PM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Sale	11.46	577,007	6,612,500	37,284,108	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Sale	11.45	565,266	6,472,296	37,861,115	Jun 23 11:35 AM
Ramaswamy Vivek	10% Owner	Jun 20 '25	Proposed Sale	11.46	577,007	6,611,850		Jun 20 04:35 PM
Venker Eric	Officer	Jun 20 '25	Proposed Sale	11.45	100,000	1,145,268		Jun 20 04:13 PM
Ramaswamy Vivek	10% Owner	Jun 18 '25	Proposed Sale	11.45	565,266	6,472,996		Jun 18 04:38 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Sale	11.34	547,430	6,207,856	38,627,181	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Sale	11.19	200,800	2,246,952	38,426,381	Jun 06 05:49 PM
Ramaswamy Vivek	10% Owner	Jun 06 '25	Proposed Sale	11.19	200,800	2,246,311		Jun 06 04:33 PM
Venker Eric	President & COO	Jun 03 '25	Option Exercise	3.85	785,026	3,022,350	2,028,501	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Option Exercise	3.85	600,000	2,310,000	1,677,197	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 03 '25	Sale	11.22	566,278	6,353,639	1,462,223	Jun 04 09:00 PM
Venker Eric	President & COO	Jun 02 '25	Sale	11.07	433,722	4,801,303	1,243,475	Jun 04 09:00 PM
Ramaswamy Vivek	10% Owner	Jun 04 '25	Proposed Sale	11.34	547,430	6,208,008		Jun 04 04:42 PM
ERIC VENKER	Officer	Jun 03 '25	Proposed Sale	11.22	566,278	6,355,961		Jun 03 05:14 PM
ERIC VENKER	Officer	Jun 02 '25	Proposed Sale	11.07	433,722	4,803,341		Jun 02 04:16 PM
Venker Eric	President & COO	May 20 '25	Option Exercise	3.85	100,000	385,000	1,177,197	May 22 09:00 PM
Venker Eric	President & COO	May 20 '25	Sale	10.95	100,000	1,095,000	1,077,197	May 22 09:00 PM
Venker Eric	Officer	May 20 '25	Proposed Sale	10.95	100,000	1,094,986		May 20 04:30 PM
Ramaswamy Vivek	10% Owner	May 07 '25	Sale	11.18	625,000	6,987,500	39,174,611	May 08 08:51 PM

MP MP Materials Corporation daily Stock Chart

Peers: REE

| Held by: VTI IJH VB XME VBK REMX VXF MDY SPMD VAW

Index	-	P/E	-	EPS (ttm)	-0.70	Insider Own	19.44%	Shs Outstand	177.21M	Perf Week	-3.72%
Market Cap	9.21B	Forward P/E	71.43	EPS next Y	0.73	Insider Trans	-2.42%	Shs Float	142.74M	Perf Month	-13.61%
Enterprise Value	8.72B	PEG	-	EPS next Q	0.05	Inst Own	69.52%	Short Float	16.91%	Perf Quarter	-23.79%
Income	-117.64M	P/S	39.57	EPS this Y	24.79%	Inst Trans	-6.89%	Short Ratio	1.87	Perf Half Y	56.19%
Sales	232.74M	P/B	4.69	EPS next Y	319.83%	ROA	-3.86%	Short Interest	24.13M	Perf YTD	233.10%
Book/sh	11.09	P/C	4.74	EPS next 5Y	-	ROE	-6.83%	52W High	100.25 -48.17%	Perf Year	214.17%
Cash/sh	10.95	P/FCF	-	EPS past 3/5Y	- -41.29%	ROIC	-3.52%	52W Low	15.56 233.95%	Perf 3Y	81.06%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-15.00% 22.66%	Gross Margin	-26.28%	Volatility	3.91% 5.02%	Perf 5Y	45.47%
Dividend TTM	-	EV/Sales	37.45	EPS Y/Y TTM	-95.87%	Oper. Margin	-68.60%	ATR (14)	3.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.51	Sales Y/Y TTM	26.44%	Profit Margin	-50.55%	RSI (14)	38.88	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	8.05	EPS Q/Q	-53.60%	SMA20	-8.07%	Beta	1.60	Target Price	78.93
Payout	-	Debt/Eq	0.44	Sales Q/Q	-14.90%	SMA50	-13.70%	Rel Volume	0.48	Prev Close	53.38
Employees	804	LT Debt/Eq	0.40	Earnings	Nov 06 AMC	SMA200	5.17%	Avg Volume	12.93M	Price	51.96
IPO	Jun 22, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	42.16% 0.59%	Trades		Volume	2,084,796	Change	-2.65%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$71
Nov-24-25	Upgrade	BMO Capital Markets	Market Perform → Outperform	$75
Nov-19-25	Initiated	Goldman	Buy	$77
Nov-14-25	Upgrade	JP Morgan	Neutral → Overweight
Nov-10-25	Upgrade	Deutsche Bank	Hold → Buy	$71
Oct-09-25	Resumed	BMO Capital Markets	Market Perform	$76
Sep-23-25	Initiated	Daiwa Securities	Outperform	$80
Aug-01-25	Upgrade	Jefferies	Hold → Buy	$80
Jul-31-25	Resumed	Morgan Stanley	Equal-Weight	$65
Jul-07-25	Downgrade	Jefferies	Buy → Hold	$33
Jun-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$34
Sep-27-24	Reiterated	Robert W. Baird	Outperform	$20 → $25
Jul-15-24	Initiated	BMO Capital Markets	Market Perform	$16.50
Apr-23-24	Downgrade	JP Morgan	Overweight → Neutral	$20 → $16
Mar-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$26 → $15.50
Sep-06-23	Upgrade	Northland Capital	Market Perform → Outperform
Aug-31-23	Initiated	JP Morgan	Overweight	$27
Apr-18-23	Downgrade	Northland Capital	Outperform → Market Perform	$32
Jul-13-22	Initiated	Canaccord Genuity	Buy	$44
Jun-06-22	Resumed	Northland Capital	Outperform	$60

Show Previous Ratings

Dec-28-25 10:00AM	MP Materials Gained 230% in 2025. Should You Buy, Sell, or Hold MP Stock for 2026? (Barchart)
Dec-25-25 10:27AM	Is USA Rare Earth the Smartest Investment You Can Make Today? (Motley Fool)
Dec-24-25 05:48PM	Forget MP Materials: This Rare Earth Stock Is Up 21% in 2025 With More Upside Ahead (Motley Fool)
Dec-23-25 12:21PM	MP vs. UUUU: Which Rare Earth Stock Has an Edge Now? (Zacks)
09:29AM	MongoDB and Acadia Healthcare have been highlighted as Zacks Bull and Bear of the Day (Zacks)
11:49AM	Loading…
Dec-22-25 11:49AM	3 Rare Earth Stocks to Watch in 2026 as the Sector Heats Up (Zacks)
Dec-19-25 11:50AM	Is VanEck Rare Earth and Strategic Metals ETF the Smartest Investment You Can Make Today? (Motley Fool)
Dec-18-25 02:35PM	Is MP Materials Stock a Millionaire Maker? (Motley Fool)
Dec-17-25 08:55AM	Why This Government-Backed Stock Could Be the Biggest Winner of 2026 (InvestorPlace)
Dec-16-25 07:00PM	Large Critical Minerals Deposit Discovered In Utah (Oilprice.com)
08:55AM	Welcome to the Presidents Market (InvestorPlace)
Dec-15-25 10:49AM	MP Expects Return to Profitability in Q4: Achievable or Too Ambitious? (Zacks) -6.00%
09:00AM	Warner Bros. Is Blockbuster Finale to $4.5 Trillion M&A Haul (Bloomberg)
Dec-14-25 08:55AM	Robotics Is About to Become Americas Most Important Industry (InvestorPlace)
08:05AM	The Smartest Mining Stock to Buy With $100 Right Now (Motley Fool)
10:18AM	Loading…
Dec-12-25 10:18AM	3 Growth Stocks to Buy and Hold for the Next Decade (Motley Fool) -5.58%
Dec-11-25 10:05AM	Is MP Stock a Buy, Hold or Sell After Its 98.9% Six-Month Rally? (Zacks)
07:44AM	Morgan Stanley Upgrades MP Materials (MP) to Overweight on US Supply Chain Push and Rare Earth Outlook (Insider Monkey)
06:20AM	Will MP Materials Stock Have Room to Run in 2026? (Motley Fool)
Dec-10-25 11:24AM	USAR Surges 52.5% YTD: How Should Investors Play the Stock? (Zacks)
Dec-09-25 04:59PM	Morgan Stanley Is Sweetening on MP Materials Stock Following Historic Deal. Should You Buy MP Here? (Barchart)
09:32AM	5 High Short-Interest Stocks to Buy Before Q1 2026 (MarketBeat)
07:00AM	Landmark Deal Gives North America Its First Heavy Rare Earth Refinery (Oilprice.com)
Dec-08-25 07:24PM	Should You Buy MP Materials Stock While It's Under $65? (Motley Fool)
11:50AM	Should You Invest $100 in MP Materials Right Now? (Motley Fool)
07:37AM	Insider Action: Multimillion dollar sell-offs across major U.S. companies (CNBC TV)
Dec-07-25 12:30PM	China Locked Onto Japanese Military Fighters. How That Could Impact Rare Earths. (Barrons.com)
Dec-05-25 03:25PM	The last holdout on MP Materials' stock has turned bullish (MarketWatch)
03:09PM	MP Materials Corp. (MP): A Bull Case Theory (Insider Monkey)
12:35PM	Wall Street Still Pounding the Table Over MP Materials, Albemarle, and Netflix (24/7 Wall St.)
07:41AM	Loading…
07:41AM	MP Materials rises as Morgan Stanley upgrades stock on strategic importance (Investing.com)
05:25AM	After Falling 41% From Its Recent Peak, Is MP Materials Stock a Buy? (Motley Fool)
Dec-03-25 09:30AM	Down 41% From Its Highs, Should You Buy the Dip in MP Materials Stock? (Barchart)
Dec-01-25 11:03PM	What does it mean when Uncle Sam is one of your biggest shareholders? Chip startup xLight is about to find out (TechCrunch) -6.21%
10:23AM	If You'd Invested $100 in MP Materials 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Nov-30-25 01:15PM	2 Monster Stocks to Hold for the Next 5 Years (Motley Fool)
Nov-29-25 09:30AM	What to Know Before Buying MP Materials Stock (Motley Fool)
07:05AM	Last Call: Why You Need to Buy This Rare-Earth Metal Stock Before Everyone Else Catches On (Motley Fool)
07:00AM	MarketBeat Week in Review - 11/24 - 11/28 (MarketBeat)
Nov-28-25 03:08PM	MP Materials: What More Could You Wish For Really (GuruFocus.com)
12:39PM	US, China are basically in a 'two-horse race' around AI (Yahoo Finance Video)
11:33AM	Here's Why MP Materials Stock Surged Higher This Week (Motley Fool)
Nov-26-25 09:35AM	5 Stocks to Buy Before Santa Claus Comes to Town (MarketBeat)
07:15AM	5 Reasons to Buy MP Materials Stock Like There's No Tomorrow (Motley Fool)
04:55AM	2 Things Every USA Rare Earth Investor Needs to Know (Motley Fool)
Nov-25-25 10:23AM	Betting on the Backbone: 3 AI Infrastructure Stocks (MarketBeat)
10:00AM	MP Materials price target lowered to $94 from $112 at BofA (TipRanks)
Nov-24-25 04:17PM	These Stocks Moved the Most Today: Alphabet, Broadcom, Tesla, Nvidia, Novo Nordisk, Oscar Health, Inspire Medical, and More (Barrons.com) +6.82%
04:15PM	JPMorgan and Goldman Upgrade MP Materials Amid Defense-Driven Demand Outlook (MarketBeat)
03:05PM	These Stocks Are Moving the Most Today: Alphabet, Broadcom, Tesla, Nvidia, Novo Nordisk, Oscar Health, Inspire Medical, and More (Barrons.com)
02:39PM	If You'd Invested $100 in MP Materials 1 Year Ago, Here's How Much You'd Have Today (Motley Fool)
12:44PM	Wall Street Just Upgraded NVDA, AMZN, and MP Again (24/7 Wall St.)
12:33PM	MP vs. USAR: Which Rare-Earth Play Looks Stronger Right Now? (Zacks)
12:12PM	BMO upgrades MP Materials on US supply chain push and Saudi JV upside (Investing.com)
11:29AM	Analysts Confident as Rare-Earths Stock Lands Another Upgrade (Schaeffer's Research)
09:20AM	Here are Mondays Top Wall Street Analyst Research Calls: Baidu, Carvana, Exact Sciences, Ferrari, Marvell Technology, Meta Platforms and More (24/7 Wall St.)
08:57AM	The U.S.-China Trade Detente Is Fragile. Soybeans Are a Warning Sign. (Barrons.com)
08:24AM	MP Materials Stock Upgraded, Price Target Cut. What It Says About Rare-Earths Plays. (Barrons.com)
07:39AM	Insider Action sees major executive stock sales (CNBC TV)
07:00AM	If You'd Invested $10,000 in MP Materials Stock 5 Years Ago, Here's How Much You'd Have Today (Motley Fool)
Nov-22-25 11:09AM	MP Materials Stock Soared After Earnings-Here's the Real Reason (MarketBeat)
Nov-21-25 04:23PM	How China Built Rare-Earth Dominance, and How the U.S. Can Fight Back (Barrons.com) +6.82%
06:00AM	Meet the company that looks to gain a foothold where China dominates rare earth elements (Yahoo Finance)
Nov-20-25 03:45PM	These 15 stocks are still showing momentum - and a market-beating edge (MarketWatch) -10.81%
03:36PM	Wall Street Sees a Buying Opportunity in This Rare Earths Stock. Should You Snap Up Shares Now? (Barchart)
03:24PM	Billionaire Gina Rinehart Is Now the Top Investor in MP Materials. Should You Follow the Money and Buy MP Stock Too? (Barchart)
06:28AM	MP Materials (MP) Jumps 8.6% on Strong Revenues, Upbeat Outlook (Insider Monkey)
04:41AM	MP Materials, US DoW announce rare earth refinery JV in Saudi Arabia (Mining Technology)
Nov-19-25 06:17PM	Why MP Materials is becoming Americas most critical rare-earth stock (TheStreet) +8.61%
04:44PM	The Department of War Is Doubling Down on MP Materials. Should You Buy MP Stock Here? (Barchart)
04:34PM	Stocks to Watch Wednesday: Alphabet, Lowe's, Target, Constellation Energy (The Wall Street Journal)
04:22PM	These Stocks Are Moving the Most Today: Nvidia, Alphabet, Lowes, Semrush, MP Materials, Constellation Energy, and More (Barrons.com)
04:22PM	Goldman Sachs Says to Buy MP Stock. Heres What It Says to Sell. (Barrons.com)
12:12PM	MP Materials gets bullish Goldman call, Plug Power stock falls (Yahoo Finance Video)
11:10AM	Analysts Tout 3 Rare Earth Stocks; Lithium Stocks Stay Hot As AI Boosts Demand (Investor's Business Daily)
11:02AM	MP Materials' NdPr Production Soars: Can Growth Continue? (Zacks)
10:45AM	US and Saudi Arabia reach deal for rare earths facility in Gulf kingdom (Financial Times)
10:11AM	MP Materials gets another government deal, this time in Saudi Arabi (MarketWatch)
09:42AM	Goldman Sachs initiates MP Materials at Buy, cites strategic U.S. alignment (Investing.com)
09:33AM	Stocks to Watch Wednesday: Lowe's, Target, Constellation Energy (The Wall Street Journal)
09:20AM	Goldman Sachs Says Buy MP Stock. Here's What It Says to Sell. (Barrons.com)
09:07AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: DoorDash, Freeport-McMoRan, GitLab, Home Depot, Medtronic, Molson-Coors, and More (24/7 Wall St.)
08:35AM	MP Stock Gets Buy Rating at Goldman. But This Rare Earth Miner Gets a Sell. (Barrons.com)
08:30AM	MP Materials and the U.S. Department of War Partner with the Saudi Arabian Mining Company (Maaden) to Develop Rare Earth Refinery Joint Venture (Business Wire)
Nov-18-25 12:41PM	The 1,500% Metal Shock: Yttrium's Wild Surge That Could Upend Global Supply Chains (GuruFocus.com)
09:25AM	NYSE Content Advisory: Pre-Market Update + Berkshire Hathaway Makes $4.3 Billion Tech Investment (PR Newswire)
06:30AM	Gina Rinehart becomes largest shareholder in MP Materials (Mining Technology)
Nov-17-25 03:11PM	Wolfspeed and 4 More Stocks That Could Get a Government Boost If Trump Keeps Investing (Barrons.com)
02:40PM	These Five Stocks Could Get a Government Boost (Barrons.com)
01:30PM	Why MP Materials (MP) Implosion Presents a Rare Upside Opportunity for Quants (Barchart)
11:47AM	MP Materials, Rare Earth Stocks Fall-Again (Barrons.com)
08:07AM	Think It's Too Late to Buy MP Materials? Here's 1 Reason Why There's Still Time. (Motley Fool)
05:00AM	The U.S. aims to breathe easy amid Chinas chokehold on rare earths, but loosening the grip takes years of concerted effort (Fortune)
04:00AM	Uncle Sam is outperforming the S&P 500 (CNN Business)
Nov-15-25 09:05AM	Is MP Materials Stock a Millionaire Maker? (Motley Fool)
Nov-14-25 04:35PM	MP Materials Stock Gets Another Upgrade. The Outlook Is Bright. (Barrons.com)
01:01PM	JPMorgan lifts MP Materials on unmatched earnings visibility (Investing.com)
10:48AM	Wall Street is Still Pounding the Table Over MP, GPS and NVDA (24/7 Wall St.)
09:38AM	Microsoft initiated, Home Depot downgraded: Wall Street's top analyst calls (The Fly)
08:04AM	MP Materials Gets Another Upgrade. Why the Stock Is Falling. (Barrons.com)

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the Materials and Magnetics segments. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Corbett Ryan	Chief Financial Officer	Dec 09 '25	Sale	60.00	38,146	2,288,760	156,666	Dec 10 09:11 PM
Corbett Ryan	Officer	Dec 09 '25	Proposed Sale	60.00	38,146	2,288,760		Dec 09 04:14 PM
Litinsky James H.	Chairman and CEO	Dec 05 '25	Sale	62.94	385,000	24,232,308	13,105,965	Dec 05 09:45 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Dec 05 '25	Proposed Sale	62.94	385,000	24,231,092		Dec 05 04:29 PM
Litinsky James H.	Chairman and CEO	Nov 20 '25	Sale	63.86	248,411	15,864,583	13,369,665	Nov 20 09:40 PM
JAMES HENRY LITINSKY REVOCABLE	Officer	Nov 20 '25	Proposed Sale	63.86	248,411	15,864,147		Nov 20 04:23 PM
Corbett Ryan	Chief Financial Officer	Nov 17 '25	Sale	57.72	20,000	1,154,400	194,812	Nov 19 09:21 PM
Corbett Ryan	Officer	Nov 17 '25	Proposed Sale	57.72	20,000	1,154,480		Nov 17 01:13 PM
Rosenthal Michael Stuart	Chief Operating Officer	Aug 29 '25	Sale	72.02	150,000	10,802,838	1,284,409	Aug 29 09:23 PM
Rosenthal Michael Stuart	Officer	Aug 29 '25	Proposed Sale	72.02	150,000	10,803,255		Aug 29 04:20 PM
Hoops Elliot Dean	General Counsel and Secretary	Aug 01 '25	Sale	60.33	6,337	382,304	0	Aug 01 09:22 PM
Hoops Elliot Dean	Officer	Aug 01 '25	Proposed Sale	60.29	6,337	382,038		Aug 01 03:58 PM
Hoops Elliot Dean	General Counsel and Secretary	Jul 01 '25	Sale	31.94	6,338	202,464	6,337	Jul 03 09:27 PM
Hoops Elliot Dean	Officer	Jul 01 '25	Proposed Sale	31.90	6,338	202,209		Jul 01 04:36 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 26 '25	Sale	36.37	5,523	200,872	69,749	Jun 27 09:30 PM
Hoops Elliot Dean	Officer	Jun 26 '25	Proposed Sale	36.33	5,523	200,651		Jun 26 04:17 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 13 '25	Sale	29.96	5,538	165,918	12,675	Jun 13 09:25 PM
Hoops Elliot Dean	General Counsel and Secretary	Jun 12 '25	Sale	29.95	800	23,960	18,213	Jun 13 09:25 PM
Hoops Elliot Dean	Officer	Jun 13 '25	Proposed Sale	29.96	6,338	189,900		Jun 13 04:30 PM
Litinsky James H.	Chairman and CEO	Apr 14 '25	Sale	27.08	199,180	5,393,794	13,643,076	Apr 16 09:11 PM
Litinsky James H.	Chairman and CEO	Mar 25 '25	Sale	27.03	396,293	10,711,800	13,860,775	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 26 '25	Sale	27.00	18,519	500,013	13,842,256	Mar 27 09:40 PM
Litinsky James H.	Chairman and CEO	Mar 20 '25	Sale	27.04	95,621	2,585,592	14,257,068	Mar 21 09:15 PM
Litinsky James H.	Chairman and CEO	Mar 18 '25	Sale	26.71	639,294	17,075,543	14,513,864	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 17 '25	Sale	26.77	489,918	13,115,105	15,153,158	Mar 19 09:18 PM
Litinsky James H.	Chairman and CEO	Mar 19 '25	Sale	26.94	161,175	4,342,054	14,352,689	Mar 19 09:18 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 19 '25	Proposed Sale	26.83	788,356	21,151,591		Mar 19 05:04 PM
Corbett Ryan	Chief Financial Officer	Mar 14 '25	Sale	25.51	60,000	1,530,391	230,100	Mar 18 06:45 PM
Corbett Ryan	Chief Financial Officer	Mar 17 '25	Sale	27.00	15,000	405,000	214,812	Mar 18 06:45 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 18 '25	Proposed Sale	26.69	721,726	19,262,867		Mar 18 05:06 PM
JAMES HENRY LITINSKY REVOCABLE	Director	Mar 17 '25	Proposed Sale	26.83	489,918	13,144,500		Mar 17 05:05 PM
Corbett Ryan	Officer	Mar 17 '25	Proposed Sale	27.00	15,000	405,000		Mar 17 04:03 PM
Corbett Ryan	Officer	Mar 14 '25	Proposed Sale	25.00	60,000	1,500,000		Mar 14 04:09 PM
Litinsky James H.	Chairman and CEO	Feb 04 '25	Sale	24.01	386,223	9,273,214	15,643,076	Feb 06 09:13 PM

ROIV

Roivant Sciences Ltd

MP

MP Materials Corporation

Upgrade your FINVIZ experience